Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Roginolisib · IOA-244, MSC-2360844

Small molecule · developed by iOnctura

Phase 1/2 Most advanced trial
1 Registered trials

What is Roginolisib?

Roginolisib (IOA-244, MSC-2360844) is an investigational agent studied in peripheral T-cell lymphoma and follicular helper T-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IOA-244, MSC-2360844
Drug type
Small molecule
Therapy area
Oncology
Developer
iOnctura
In trials of
ABBV, BMY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
6K8FC2TF54

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07018752 Phase 1/2 Peripheral T Cells Lymphoma (PTCL) Recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Follicular Helper T-Cell LymphomaPeripheral T Cells Lymphoma (PTCL)

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.